MARKSANS PHARMA
Back to Balance Sheet
|
MARKSANS PHARMA Last 5 Year Total Current Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Total Current Liabilities | ₹390 Cr | ₹341 Cr | ₹380 Cr | ₹299 Cr | ₹229 Cr |
What is the latest Total Current Liabilities ratio of MARKSANS PHARMA ?
Year | Total Current Liabilities |
---|---|
Mar2024 | ₹390 Cr |
Mar2023 | ₹341 Cr |
Mar2022 | ₹380 Cr |
Mar2021 | ₹299 Cr |
Mar2020 | ₹229 Cr |
How is Total Current Liabilities of MARKSANS PHARMA Trending?
Years | Total Current Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹390 Cr | 14.33 | |
Mar2023 | ₹341 Cr | -10.29 | |
Mar2022 | ₹380 Cr | 27.13 | |
Mar2021 | ₹299 Cr | 30.69 | |
Mar2020 | ₹229 Cr | - |
Compare Total Current Liabilities of peers of MARKSANS PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
MARKSANS PHARMA | ₹13,120.1 Cr | -5% | -15% | 62.5% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹444,873.0 Cr | -1.9% | 2.7% | 42.3% | Stock Analytics | |
DIVIS LABORATORIES | ₹156,544.0 Cr | -2.9% | -3.8% | 46.1% | Stock Analytics | |
CIPLA | ₹120,964.0 Cr | -2.2% | 1.4% | 14.7% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹112,710.0 Cr | -1.4% | 7.8% | 13.9% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹100,744.0 Cr | 2.8% | 0.6% | 35.5% | Stock Analytics |
MARKSANS PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
MARKSANS PHARMA | -5% |
-15% |
62.5% |
SENSEX | 0.1% |
-4.4% |
8.8% |
You may also like the below Video Courses